Navigation Links
Tokai Pharmaceuticals' galeterone well-tolerated in patients with advanced prostate cancer
Date:3/31/2012

CAMBRIDGE, Mass. and CHICAGO, Ill. -- Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer (CRPC) in a Phase 1 study. The data will be presented in an oral presentation titled, "ARMOR1: Safety of galeterone (TOK-001) in a Phase 1 clinical trial in chemotherapy nave patients with castration-resistant prostate cancer (CRPC)," abstract number CT-07, on Tuesday, April 3, 2012 at 3:05 p.m. (CDT) at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago.

CRPC is an advanced, difficult-to-treat form of prostate cancer that occurs when the disease progresses despite the use of anti-hormonal therapies. Galeterone is a small molecule, oral drug for the treatment of CRPC that disrupts the growth and survival of prostate cancer cells via a novel and proprietary triple mechanism of action.

"Because currently available therapeutic options to treat castration-resistant prostate cancer are limited, often poorly-tolerated and may fail because of resistance, patients are in urgent need of new safe and effective treatments," said Mary-Ellen Taplin, M.D., associate professor of medicine, director of genitourinary clinical research, Dana-Farber Cancer Institute, Harvard Medical School and co-lead researcher in the study. "These Phase 1 galeterone data, demonstrating minimal toxicities, improved PSA response and a reduction in tumor size, are exciting for those of us in the medical community treating this life-threatening cancer. I look forward to following the further development of galeterone as a promising approach in the treatment of prostate cancer."

The ARMOR1 study was led by co-principal investigators Dr. Taplin and Bruce Montgomery, M.D., associate professor of medical oncolo
'/>"/>

Contact: Caton Lovett
caton@purecommunicationsinc.com
910-232-7166
Pure Communications Inc.
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. From scourge to saint: E. coli bacteria becomes a factory - to make cheaper, faster pharmaceuticals
2. 2012 Biotechnology and Pharmaceuticals: Forthcoming Conferences and Exhibitions
3. Study finds an increase of children accidentally poisoned with pharmaceuticals
4. Study Shows Sutro Biopharmas Biochemical Protein Synthesis Technology Enables Rapid Production and Scale-Up of Biopharmaceuticals
5. PharmaEngine, Inc. and Merrimack Pharmaceuticals, Inc. Enter into a Licensing and Collaboration Agreement on PEP02 (MM-398), Nanoliposomal Irinotecan
6. Environmental risk assessment of pharmaceuticals inadequate
7. Brown licenses potential muscular dystrophy treatment to Tivorsan Pharmaceuticals
8. CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks
9. Biostar Pharmaceuticals, Inc. Receives New Advertising Approval from Shaanxi SFDA for Marketing Xin Aoxing Capsule
10. NIH awards $8.5 million for research on pharmaceuticals for children
11. TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
(Date:4/1/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces the second shipment of a ... early access pre-order customers. Feedback from ... including Walmart, Target, AT&T, Dunkin, Donuts, Stop & Shop ... all outlets and very easy to use. Several users ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... 2010) The Association for Molecular Pathology (AMP) invites ... Annual Meeting and Exhibits and learn about the latest ... four-day event will feature more than 100 corporate exhibits, ... sessions. The keynote speaker is the distinguished recipient of ...
... Chemicals pervade our lives. While the benefits to society ... enabling safer, more efficient and more convenient consumer products ... side. Today, a growing awareness of the risks posed ... stimulated intensive investigations into their lifecycle and the unintended ...
... women who undergo in vitro fertilization (IVF) procedures suffer from ... therapy involved in IVF procedures is primarily responsible for this. ... this is true, other factors are even more influential. ... University,s Sackler Faculty of Medicine and the Sourasky Medical Center ...
Cached Biology News:New book examines health and environmental impacts of common (and not-so-common) chemicals 2New book examines health and environmental impacts of common (and not-so-common) chemicals 3Overcoming the IVF baby blues 2Overcoming the IVF baby blues 3
(Date:5/20/2015)... , May 20, 2015  Health eCareers, the ... healthcare organizations with job seekers looking for the ... a new mobile and online tool dedicated exclusively ... industry. SHIFT enables employers to quickly ... travel nursing, per diem and other temporary positions, ...
(Date:5/20/2015)...  Haemonetics Corporation (NYSE: HAE ) announced today ... present at The Jefferies 2015 Global Healthcare Conference in ... st , 2015 at 8:30am Eastern time.  ... via webcast at: http://wsw.com/webcast/jeff88/hae ... is a global healthcare company dedicated to providing innovative ...
(Date:5/20/2015)... DUBLIN , May 19, 2015 Research ... announced the addition of the "Bone Morphogenetic ... Spinal Fusion, Trauma, Reconstructive and Oral - Maxillofacial) ... and Forecast 2014 - 2022" report to ... proteins market is studied based on the types ...
(Date:5/20/2015)... The Greater Gift Initiative, Inc ., ... to announce they are donating 10,010 vaccines today in ... the effort and commitment of clinical trial volunteers who ... in 2014. , With a mission to advance ... trial participation, GGI supports International Clinical Trials Day and ...
Breaking Biology Technology:Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3Global Bone Morphogenetic Proteins Market Industry Analysis 2014 - 2022 2The Greater Gift Initiative Donates over 10,000 Vaccines in Honor of International Clinical Trials Day 2
... Society of Forensic Toxicologists (SOFT) recognizes the recent ... Strengthening Forensic Science in the United States: A ... within the forensic sciences where improvements may be ... education, training, accreditation and certification in forensic science. ...
... superior to synthetic HRT with greater cardiovascular benefits ... 23 The most comprehensive analysis to date, ... peer-reviewed publication for practicing clinicians, showed that bioidentical ... are more efficacious than their synthetic counterparts. Conducted ...
... BOZEN, Italy, February 23 Health Robotics ... a definitive agreement whereby Can-Med,has acquired the ... in Armenia, Georgia, Kazakhstan, Uzbekistan, Azerbaijan,Iran, Mongolia, ... first and only automated, point-of-care-distributed, and fail-safe,robotic ...
Cached Biology Technology:The Society of Forensic Toxicologists Comments on the National Academy of Sciences' Report on 'Strengthening Forensic Science in the United States' 2New Analysis Finds Bioidentical Hormones Safer Than Standard Hormone Replacement Therapy 2New Analysis Finds Bioidentical Hormones Safer Than Standard Hormone Replacement Therapy 3Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central Asia 2Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central Asia 3
... MMP-3, Human, Assay, 96 wells. ELISA.Specific ... and complexed MMP-3. No cross-reactivity with MMP-1, ... ng/ml.Suitable for use with cell culture supernatant, ... at -15 to -30 C. Category: ...
... Steady gravity-fed delivery of buffer ... animal perfusion. Rat version. In Vivo ... results--Steady gravity-fed delivery of buffer and ... Easy to setup, use and clean--Complete ...
... 8 micro-bore tubes to 1 outflow ... tips, Rapid (several millisecond) solution change ... prevention , Solid construction 360, 250 ... For mounting on any micromanipulator Available ...
... The steadylite plus assay ... High assay sensitivity, Designed for ... Suitable for higher density microplates ... plates, Odor free, Convenient storage ...
Biology Products: